Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic simplification with thymidine analogue-sparing regimens in patients on effective HAART
2005-004025-26Phase 3Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Sep 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of zidovudine, stavudine, didanosine, lamivudine, zalcitabine and 2 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Virologic efficacy. Started Sep 2007; status: completed.
02
Drugs
zidovudinestavudinedidanosinelamivudinezalcitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-004025-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004025-26.